Biosimilars Add “Urgency” To Medicare Payment Reforms – MedPAC Commissioner
Executive Summary
Developing alternatives to the ASP-based reimbursement system for Medicare Part B drugs may become increasingly important to ensure the program will benefit from lower-cost biosimilars, Georgetown’s Jack Hoadley points out.